tiprankstipranks
Atossa Therapeutics (GB:0HJ7)
LSE:0HJ7

Atossa Therapeutics (0HJ7) Share Price & Analysis

0 Followers

Financials

Annual

Options Prices

Currently, No data available
---

Ownership Overview

7.41%5.68%8.01%78.90%
8.01% Other Institutional Investors
78.90% Public Companies and
Individual Investors

0HJ7 FAQ

What was Atossa Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Atossa Therapeutics’s market cap?
Currently, no data Available
When is Atossa Therapeutics’s upcoming earnings report date?
Atossa Therapeutics’s upcoming earnings report date is Aug 14, 2024 which is in 29 days.
    How were Atossa Therapeutics’s earnings last quarter?
    Currently, no data Available
    Is Atossa Therapeutics overvalued?
    According to Wall Street analysts Atossa Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
      Does Atossa Therapeutics pay dividends?
      Atossa Therapeutics does not currently pay dividends.
      What is Atossa Therapeutics’s EPS estimate?
      Atossa Therapeutics’s EPS estimate is -$0.06.
        How many shares outstanding does Atossa Therapeutics have?
        Atossa Therapeutics has 125,757,416 shares outstanding.
          What happened to Atossa Therapeutics’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Atossa Therapeutics?
          Among the largest hedge funds holding Atossa Therapeutics’s share is Graham Capital Management, L.P.. It holds Atossa Therapeutics’s shares valued at N/A.
            ---

            Company Description

            Atossa Therapeutics

            Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests. The ForeCYTE Breast Health Test provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65. The ArgusCYTE Breast Health Test offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.
            ---

            0HJ7 Earnings Call

            Q2 2023
            0:00 / 0:00
            ---

            0HJ7 Stock 12 Month Forecast

            Average Price Target

            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
            Similar Stocks
            Company
            Price & Change
            Follow
            Atossa Therapeutics
            Advaxis
            Geron
            Regulus
            Sorrento Therapeutics

            Best Analysts Covering 0HJ7

            1 Year
            Jason McCarthyMaxim Group
            1 Year Success Rate
            8/10 ratings generated profit
            80%
            1 Year Average Return
            +37.59%
            reiterated a buy rating 2 months ago
            Copying Jason McCarthy's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +37.59% per trade.
            Popular Stocks
            ---
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis